Latest News and Press Releases

Mechelen, Belgium, Aug. 12, 2005 (PRIMEZONE) -- Galapagos: - Financials on target for 2005 increased annual revenues and cash burn of around 7 million euro - Initial public offering...

MECHELEN, Belgium and NEW YORK, Aug. 12, 2005 (PRIMEZONE) -- The High Q Foundation Inc., a foundation that supports research aimed at finding diagnoses, treatments, cures and preventions of...

MECHELEN, Belgium, Aug. 10, 2005 (PRIMEZONE) -- Galapagos NV, ZoBio BV, Pyxis Discovery BV and Leiden University announced today the formation of a four-way collaboration to pursue a small molecule...

MECHELEN, Belgium, Aug. 2, 2005 (PRIMEZONE) -- Galapagos NV, a genomics-based drug discovery company (Euronext:GLPG) announced today that it will release its financial results for the first half of...

MECHELEN, Belgium, July 6, 2005 (PRIMEZONE) -- Galapagos announced today that it has entered into a research collaboration with Novartis Pharmaceuticals UK Limited. Under the agreement, Galapagos'...

ROCKVILLE, M.D. and MECHELEN, Belgium, June 20, 2005 (PRIMEZONE) -- Galapagos today announced that it has entered into a services agreement with Celera Genomics Group (NYSE:CRA), an Applera...

MECHELEN, Belgium, May 24, 2005 (PRIMEZONE) -- Galapagos NV, a genomics-based drug discovery company, announces changes to its Board of Directors. In view of Galapagos' listing on Euronext Amsterdam...

MECHELEN, Belgium, Jan. 5, 2005 (PRIMEZONE) -- Galapagos today announced that it has entered into a target licensing and multi-year target identification collaboration in respiratory and inflammatory...

MECHELEN, Belgium, Sept. 22, 2004 (PRIMEZONE) -- Galapagos Genomics NV, Europe's leading target discovery company, announced today that it has created a new business unit for its viral based...

MECHELEN, Belgium, June 7, 2004 (PRIMEZONE) -- Galapagos Genomics NV, Europe's leading target discovery company, announced today that it has identified, validated and filed patent applications on...